Non-steroidal anti-inflammatory drug and aspirin use and the risk of head and neck cancer

British Journal of Cancer

Volumn 108, Issue 5, 2013, Pages 1178-1181

  Wilson, J C ^a   Murray, L J ^a   Hughes, C M ^b   Black, A ^c   Anderson, L A ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

aspirin; cohort study; head and neck cancer; ibuprofen

Indexed keywords

ACETYLSALICYLIC ACID; IBUPROFEN;

ADULT; AGED; ALCOHOL CONSUMPTION; CANCER RISK; CANCER SCREENING; COHORT ANALYSIS; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SMOKING; UNITED STATES;

AGED; ALCOHOL DRINKING; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IBUPROFEN; MALE; MIDDLE AGED; RISK; SMOKING; UNITED STATES;

EID: 84875468113     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.73     Document Type: Review

References (22)

1. Ahmadi N, Goldman R, Seillier-Moiseiwitsch F, Noone A, Kosti O, DavidsonBJ (2010) Decreased risk of squamous cell carcinoma of the head and neckin users of non-steroidal anti-inflammatory drugs. (published online) .Int J Otolaryngol doi 10.1155/2010/424161.
2. Altorki HK, Subbaramaiah K, Dannenberg AJ (2004) COX-2 Inhibition inupper aerodigestive tract tumors. Semin Onco 31: 30-35.
3. Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C (2012) Aspirin andcancer risk: a quantitative review to 2011. Ann Oncol 23: 1403-1415.
4. Bosetti C, Talamini R, Franceschi S, Negri E, Garavello W, La Vecchia C (2003) Aspirin use and cancers of the upper aerodigestive tract.Br J Cancer 88: 672-674.
5. Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G (2009) Aspirin, salicylates, and cancer. Lancet 373: 1301-1309.
6. Freedman ND, Schatzkin A, Leitzmann MF, Hollenbeck AR, Abnet CC (2007) Alcohol and head and neck cancer risk in a prospective study. Br J Cancer96: 1469-1474.
7. Friis S, Poulsen A, Pedersen L, Baron JA, Sorensen HT (2006) Use ofnonsteroidal anti-inflammatory drugs and risk of oral cancer: a cohortstudy. Br J Cancer 95: 363-365.
8. Friis S, Sørensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH (2003) Apopulation-based cohort study of the risk of colorectal and other cancersamong users of low-dose aspirin. Br J Cancer 88: 684-688.
9. Hunter KD, Parkinson K, Harrison PR (2005) Profiling early headand neck cancer. Nat Rev Cancer 5: 127-135.
10. Hwang DH, Fung V, Dannenberg AJ (2002) National Cancer Instituteworkshop on chemopreventive properties of nonsteroidal antiinflammatorydrugs: role of cox-dependent and-independentmechanisms. Neoplasia 4: 91-97.
11. Jayaprakash V, Rigual NR, Moysich KB, Loree TR, Nasca MA, Menezes RJ, Reid ME (2006) Chemoprevention of head and neck cancer withaspirin: a case-control study. Arch Otolaryngol Head Neck Surg 132:1231-1236.
12. Kashfi K, Ragas B (2005) Cancer prevention: a new era beyondcyclooxygenase-2. J Pharmacol Exp Ther 314: 1-8.
13. Liao Z, Mason KA, Milas L (2007) Cyclo-oxygenase-2 and its inhibition incancer. Is there a role? Drugs 67: 821-845.
14. Llewellyn CD, Johnson NW, Warnakulasuriya KAAS (2001) Risk factors forsquamous cell carcinoma of the oral cavity in young people-a completeliterature review. Oral Oncol 37: 401-418.
15. Mohan S, Epstein JB (2003) Carcinogenesis and cyclooxygenase: the potentialrole of COX-2 inhibition in upper aerodigestive tract cancer. Oral Oncol39: 537-546.
16. Pereg D, Lishner M (2005) Non-steroidal anti-inflammatory drugs for theprevention and treatment of cancer. J. Intern Med 258: 115-123.
17. Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, FogelR, Gelmann EP, Gilbert F, Hasson MA, Hayes RB, Johnson CC, MandelJS, Oberman A, O'Brien B, Oken MM, Rafla S, Reding D, Rutt W, Weissfeld JL, Yokochi L, Gohagan JK. Prostate, Lung, Colorectal andOvarian Cancer Screening Trial Project Team (2000) Design of theprostate, lung, colorectal and ovarian (PLCO) cancer screening trial.Control Clin Trials 21: 273S-309S.
18. Ramqvist T, Dalianis T (2010) Oropharyngeal cancer epidemic and humanpapillomavirus. Emerg Infect Dis 16: 1671-1677.
19. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, Meade TW (2010) Long-term effect of aspirin on colorectal cancerincidence and mortality: 20-year follow-up of fi ve randomised trials.Lancet 376: 1741-1750.
20. Subbaramaiah K, Dannenberg AJ (2007) Cyclooxygenase-2 transcription isregulated by human papillomavirus 16 E6 and E7 oncoproteins: evidenceof a corepressor/coactivator exchange. Cancer Res 67: 3976-3985.
21. Wang Z (2005) The role of COX-2 in oral cancer development, andchemoprevention/treatment of oral cancer by selective COX-2 inhibitors.Curr Pharm Des 11: 1771-1777.
22. Wilson JC, Anderson LA, Murray LJ, Hughes CM (2011) Non-steroidal antiinflammatorydrug and aspirin use and the risk of head and neck cancer: asystematic review. Cancer Causes Control 22: 803-810.